Kyntra Bio, Inc. (KYNB)

The investment case for Kyntra Bio is currently broken by a catastrophic multi-year price collapse and deteriorating operational metrics. While the company recently rebranded from FibroGen to signal a strategic pivot toward oncology and rare diseases, the market has punished this transition severely. The stock has lost over 98% of its value over the last nine years, with seven consecutive years of negative annual returns ending in a sharp 70% drop last year. This sustained trajectory suggests the market views the new strategy as insufficient to reverse the decline, despite the company reporting a positive 36.5% revenue growth and a surprisingly high 22% profit margin—figures that likely reflect the accounting treatment of a spin-off or restructuring rather than sustainable core profitability. The balance sheet shows significant distress, with negative book value and negative operating cash flows, even though free cash flow appears positive due to non-operating items. With no dividend history and a forward P/E that is mathematically meaningless due to negative earnings, there is no margin of safety. The recent price action shows a modest bounce off lows, but without a proven track record of success under the new management or a clear path to profitability, the risk of further capital destruction remains extreme.